Log In
Print
BCIQ
Print
Print this Print this
 

BAY41-6551, NKTR-061, Amikacin Inhale

  Manage Alerts
Collapse Summary General Information
Company Nektar Therapeutics
DescriptionSecond-generation nebulizer delivery of amikacin
Molecular Target Ribosomal 30S subunit
Mechanism of ActionRibosomal 30S subunit inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationPneumonia
Indication DetailsTreat Gram-negative pneumonia in intubated and mechanically ventilated patients; Treat Gram-negative pneumonia in mechanically ventilated patients; Treat hospital-acquired pneumonia (HAP); Treat ventilator-associated pneumonia (VAP)
Regulatory Designation

U.S. - Qualified Infectious Disease Program (Treat Gram-negative pneumonia in intubated and mechanically ventilated patients)

Partner

Bayer AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today